Five ways Trump’s proposed budget could hurt — and help — biopharma

resident Trump’s proposed budget for 2018, rife with deep cuts including a 20 percent funding reduction for the National Institutes of Health, has been greeted with a chorus of dismay from biopharma scientists and executives.

Consider the words used by industry veterans interviewed by STAT: “Pretty horrifying.” “A tragedy.” “Appalling.” “Incredibly short-sighted.” (One exception was the drug industry’s top lobbying group PhRMA, which put out a statement that … didn’t say much of anything.)

This is a STAT Plus article and is only available to STAT Plus subscribers.To read the full story, subscribe to STAT Plus or log in to your account.Good news: your first 30 days are on us.